NeuroBo Pharmaceuticals Files 8-K
Ticker: MTVA · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financial-statements
TL;DR
NeuroBo Pharma filed an 8-K on July 30th. Standard disclosure stuff.
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on July 30, 2024, to report on Regulation FD disclosures and financial statements. The filing indicates the company's principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138.
Why It Matters
This filing provides an update on NeuroBo Pharmaceuticals' regulatory disclosures and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- July 30, 2024 (date) — Date of Report
- 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138 (location) — Principal executive offices
- Gemphire Therapeutics Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for NeuroBo Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 30, 2024.
What is the address of NeuroBo Pharmaceuticals, Inc.'s principal executive offices?
The address of NeuroBo Pharmaceuticals, Inc.'s principal executive offices is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138.
What was NeuroBo Pharmaceuticals, Inc. formerly known as?
NeuroBo Pharmaceuticals, Inc. was formerly known as Gemphire Therapeutics Inc.
In which state was NeuroBo Pharmaceuticals, Inc. incorporated?
NeuroBo Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 718 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-07-30 08:30:18
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240730x8k.htm (8-K) — 46KB
- nrbo-20240730xex99d1.htm (EX-99.1) — 14KB
- nrbo-20240730x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240730xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-010321.txt ( ) — 234KB
- nrbo-20240730.xsd (EX-101.SCH) — 3KB
- nrbo-20240730_lab.xml (EX-101.LAB) — 16KB
- nrbo-20240730_pre.xml (EX-101.PRE) — 10KB
- nrbo-20240730x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 30, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. ("MTHERA") with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report") and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated July 30, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: July 30, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer